Articles tagged with Circulating Tumor Cells
Cancer cell-derived small extracellular vesicles can be excreted into urine, according to researchers who tracked their journey in mouse models. The study reveals that glomerular cells actively transport sEVs across the filtration barrier, supporting their use in emerging urine-based cancer diagnostics.
A new AI-powered algorithm, M-PACT, uses liquid biopsy to classify pediatric brain tumors based on DNA methylation patterns. The technology has been shown to achieve a high sensitivity rate of 92% in identifying brain tumors.
Researchers found that patients with circulating tumor DNA (ctDNA) positive after neoadjuvant therapy had a higher risk of disease recurrence, regardless of pathologic complete response. Patients who cleared ctDNA after treatment experienced improved recurrence-free survival.
The UNC Lineberger Comprehensive Cancer Center has developed an adaptive clinical trial for metastatic breast cancer, leveraging $28 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). The study aims to adapt treatment plans in near real-time using tumor biopsies, blood samples, and biomarkers.
A circulating tumor DNA-based blood test demonstrated acceptable accuracy for colorectal cancer detection in an average-risk population. However, it struggled to detect advanced precancerous lesions, highlighting the need for further improvements.
Researchers developed a 3D in vitro culture system to study tumor cell behavior, finding that clusters can infiltrate blood vessels by disrupting the endothelial barrier. This discovery suggests new targets for cancer treatment strategies.
The project aims to enhance CTC detection sensitivity and specificity for clinical needs in cancer early screening, diagnosis and treatment. The team will develop an integrated system covering CTC counting, classification and downstream detection of CTC proteins and genes.
A new study published in Nature Medicine shows a promising approach to preventing metastases in breast cancer patients. Researchers found that administering digoxin reduced circulating tumour cell clusters by an average of 2.2 cells, significantly decreasing the risk of metastasis.
Researchers have developed a way to detect circulating tumor cells in the bloodstream using biolasers, which can provide valuable information about the DNA organization inside cancer cells. The technique has been successfully tested on pancreatic and lung cancer patients, showing high accuracy rates of up to 99%.
This review provides a comprehensive overview of CTC detection methods, their association with HCC progression, and their role in prognostication and treatment monitoring. Studies show that the number of CTCs correlates with tumor size, grade, and overall cancer severity.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
Researchers developed DiFC, a two-color diffuse flow cytometry system that detects rare cancer cells in the bloodstream without invasive methods. The technology provides insights into cancer progression and response to treatments by studying different subpopulations of cancer cells simultaneously.
Researchers have identified a novel protein FOXF1 that stabilizes blood vessels inside lung tumors, decreasing intertumoral hypoxia and preventing lung cancer metastases. Increasing levels of FOXF1 or FZD4 shows promise to improve therapeutic outcomes in lung cancer patients.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
Researchers examine translational studies on peripheral surrogates of tumor burden, including circulating tumor DNA, miRNA, and HPV-specific antibodies, to inform chemotherapy and immunotherapy strategies. These biomarkers show promise as prognostic and predictive markers of response to treatment.
Researchers develop a new technique to detect circulating tumor cells in blood, overcoming noise issues with existing methods. The dual-ratio approach enhances penetration range and accuracy, paving the way for quicker diagnosis of metastasis.
A new multiplex assay has been developed to assess activated p300/CBP in circulating prostate tumor cells, revealing correlations with clinical outcomes and potential therapeutic targets for castration-resistant prostate cancer. The study found that patients with upregulated p300/CBP activity had shorter response times to ARSI therapy.
The SWOG Cancer Research Network will present 30 abstracts at the ASCO 2023 annual meeting, highlighting primary results from trials S1011, S1826, S1714, and S1929. Additionally, analysis from the S1609 DART trial will be shared publicly during the meeting.
Researchers developed glass filters to capture tumor cells from blood samples, enabling more efficient culture of these cells. The optimized filter design enhances the accuracy of cancer detection, allowing for earlier treatment and improved patient health.
Researchers developed a new device that detects and analyzes cancer cells in blood samples, enabling doctors to avoid invasive biopsies and monitor treatment progress. The Static Droplet Microfluidic device uses metabolic signatures to differentiate tumour cells from normal blood cells.
Researchers at Tokyo Medical and Dental University developed a new technique to detect breast cancer-related markers using transistors, offering a less invasive method for monitoring patients. The system successfully detected epidermal growth factor receptor expression on cancer cells.
Researchers found that circulating cancer cells form metastases mainly during sleep phases, with higher cell division rates at night, suggesting a link between hormone regulation and tumor growth. This discovery highlights the need for healthcare professionals to record the time of biopsies to ensure comparable data.
Researchers developed a fully automated technique to isolate rare circulating tumor cells from patient blood samples, revealing the diversity of cancer cells in the body. The method's accuracy was confirmed through DNA testing, allowing for personalized treatment strategies to be modified.
Researchers have identified a process to study circulating tumor cells responsible for cancer recurrence in patients with non-small cell lung cancer. The study models showed that these cells correlated with cancer recurrence, and blocking a protein called MYC made the tumor cells more vulnerable to chemotherapy.
Researchers developed a new method to detect circulating tumor cells in NSCLC patients, identifying a CK-negative CTC population associated with metastasis and drug resistance. The use of hexokinase-2 as a biomarker revealed this novel CTC population in 50% of analyzed patients.
Researchers have developed a system to capture and 'farm' natural killer immune cells from the blood to harvest their cancer-killing exosomes. The technology uses a microfluidic chip and ExoBeads to isolate NK exosomes, which are more stable and easier to modify for therapeutic purposes.
A new method of detecting circulating tumor cells (CTCs) has been developed using a powerful label-free detection method and machine learning algorithm. The technique achieved an overall accuracy of 88.6% in patient blood samples and 97% on cultured cells, outperforming existing methods.
A new study from Tulane University has identified a protein on tumor-derived extracellular vesicles that indicates if NSCLC tumors are likely to metastasize. This discovery could lead to the development of an early diagnostic test for patients at high risk of cancer spread.
Researchers found that WDR74 protein enhances the ability of circulating tumor cells to metastasize in both lung cancer and melanoma. The protein's presence increases oncogenic properties, while its absence decreases metastatic potential.
A study led by Newcastle University has identified circulating neuroblastoma tumour cells in the blood and bone marrow, providing new insights into the disease's progression. The discovery could enable non-invasive testing of targeted treatments and improve patient outcomes.
Researchers at NYU Abu Dhabi have developed a novel tool called the Micro-Electro-Fluidic Probe (MeFP) that can selectively separate and pattern mammalian cells in an open microfluidic system. The device demonstrates high isolation efficiency, separation purity, and fast pattern deposition rates.
Researchers have developed a new cytometry platform to detect rare cells in blood with high throughput and low cost. The technique uses magnetic bead labelling and alternating magnetic fields to enrich and detect target cells, achieving a limit of detection of 10 cells per millilitre.
A study describes a microfluidic system to concentrate and encapsulate circulating tumor cells, which are cancer cells that can travel through the bloodstream. Experiments with prostate cancer cells revealed high matrix metalloprotease enzyme activity.
Researchers at UCLA have created a quick and effective mechanism to measure how circulating tumor cells perform functions that drive disease, such as producing proteins that degrade tissue. The new approach enables scientists to understand how tumor cells act, rather than just what they are made from.
A magnetic wire used to snag scarce tumor cells could prove swift and effective for early cancer detection. The technique attracts up to 80 times more tumor cells than current methods, making it a potent tool to catch the disease earlier.
A new sensor detects prostate cancer cells in blood samples with high efficiency, using a low-cost method that resembles Velcro. The device captures tumor cells from circulation, enabling doctors to diagnose the disease earlier and monitor its effectiveness.
A microfluidic device developed by Lehigh University engineers can capture and release circulating tumor cells with high efficiency. The device's wavy-herringbone design and magnetic particles allow for selective capture of tumor cells while rejecting unwanted blood cells, enabling early cancer detection and treatment evaluation.
New research confirms blood flow plays a crucial role in cancer metastasis by regulating the position of circulating tumor cells and their exit from the vasculature. The study found that slower blood flow rates are associated with increased metastasis development.
Researchers have developed a method to capture circulating tumor cells, which could provide an additional way to track treatment progress or screen for disease. The technology shows promise in reducing the number of circulating tumor cells during successful radiation therapy, suggesting potential as a predictive biomarker.
The VTX-1 Liquid Biopsy System is a commercial, automated instrument that isolates clinically relevant CTC populations directly from whole blood. It achieves high recovery rates of spiked breast and lung cancer cell lines, with purities as low as <100 white blood cells per mL of processed blood.
Researchers at UC Berkeley have created a microfluidic device that can analyze individual tumor cells for specific cancer protein biomarkers. This technology could allow doctors to monitor treatment response through regular blood draws, potentially leading to more precise cancer diagnoses.
A new technique separates circulating tumor cells from whole blood at a liquid-liquid interface, capturing 95% of CTCs in one minute. This method enables early detection and monitoring of metastatic disease, improving cancer treatment outcomes.
A new UBC-developed method isolates cancer cells that have escaped from a tumour, paving the way for improved diagnosis and treatment. The device captures cells based on their internal structure, producing fewer false positives compared to conventional methods.
Researchers developed a method to isolate circulating tumor cells from blood samples using gas microbubbles. The technique successfully isolated up to 80% of cancer cells in some cases, offering a rapid and inexpensive way to analyze these rare and fragile cells.
Researchers found CTCs in 100% of patients with suspected tumors, but only 4% detected through peripheral blood. Portal vein samples provided more accurate tumor cell information, enabling better clinical decisions. The test could help predict patient outcomes and guide treatment options.
A new microchip design captures circulating tumor cells for serial analysis, while a 3D hydrogel scaffold enables retrieval and in vitro growth promotion. The technology also facilitates xenograft models in immunodeficient mice, offering a promising approach to personalized cancer therapies.
A new device has been developed to visualize and differentiate between cancer cells in the bloodstream, enabling a more focused understanding of tumour properties. This technology shows promise for better diagnosis and improved patient outcomes by identifying aggressive tumours and metastatic disease.
Researchers have devised a new way to separate cells by exposing them to sound waves as they flow through a tiny channel, overcoming existing cell-sorting technologies' limitations. The device successfully recovered about 71 percent of breast cancer cells from white blood cells in tests.
Researchers developed a method to label and track single tumor cells circulating in the blood using photoswitchable fluorescent proteins. This advance could help understand cancer spread and prevent metastasis. The technology allows for real-time tracking of individual cells in the bloodstream.
Researchers have developed an ultrasensitive nanoprobe that can detect just four circulating tumor cells in the bloodstream, surpassing traditional enzyme-based methods. This breakthrough system uses Fe3O4 nanoparticles to electrochemically sense cancer cells and offers a robust solution for early cancer detection.
Scientists from the University of Granada have developed a technique that uses circulating tumour cells and genetic markers to predict patient response to chemotherapy. This study has been awarded at the 9th International Symposium on Minimal Residual Cancer in Paris.
A recent study found that detecting changes in circulating tumor cells (CTC) may be more accurate than tracking prostate-specific antigen (PSA) levels to predict treatment outcomes in patients with castration-resistant prostate cancer. The study showed a favorable change in CTC detection occurred in over half of patients during chemoth...
Researchers at the University of Michigan have developed a microfluidic chip that can capture elusive circulating tumor cells from blood, supporting their growth for further analysis. This technology has the potential to revolutionize cancer diagnosis and treatment by providing accurate prognoses and testing treatment options on cultur...
A team of researchers at Baylor College of Medicine has identified a signature of biomarkers that identifies circulating breast tumor cells destined to seed the brain with deadly cancer. The study shows limitations of current platforms used to identify cancer in this way, but also offers new hope for diagnosis and treatment.
Researchers at the University of Michigan have devised a system to capture and study circulating tumor cells, which carry cancer around the body. The device uses nanoscale roughness to trap cancer cells regardless of their surface proteins or physical sizes.
Researchers at the University of Iowa discovered that cancer cells are surprisingly resilient to fluid forces in the bloodstream, which could help improve liquid biopsy approaches for detecting cancer cells. The study's findings suggest that resistance to fluid shear stress may be a key characteristic of malignant cells.
A novel microchip device, inspired by sea creatures' long appendages, can detect and capture rare cancer cells from whole blood patient samples. The device's three-dimensional DNA network targets specific molecules, allowing for efficient cell capture and high purity.
Researchers have developed a new microfluidic device that can separate rare cells and blood components with high accuracy and speed. The device uses inertial microfluidics to sort blood into different streams, allowing for rapid diagnosis of conditions such as anemia, malaria, or leukemia.
Researchers at the University of Granada have identified genetic and phenotypic changes that lead to tumor progression and metastasis. Circulating tumor cells can adapt to hostile environments and resist treatment, causing metastasis.
French researchers have reported the strongest proof yet that circulating tumor cells found in patient blood are linked to poor outcomes. The study suggests using a threshold of 1 CTC for defining high-risk patients, supporting its use in non-metastatic breast cancer patients.